W. L. Gore & Associates (Gore) announced the release of three-year data from the Gore ASSURED Clinical Study (ASSURED Study) in the September 2024 online issue of JACC: Cardiovascular Interventions, evaluating the long-term safety and efficacy of treating ostium secundum ASDs with the GORE® CARDIOFORM ASD Occluder.
The ASSURED Study data demonstrated long-term safety and efficacy of the GORE CARDIOFORM ASD Occluder at 6, 12 and 36 months, with 100 percent closure success* rate among patients evaluated at 36 months (n = 357).
